DSNKY News and Press, Daiichi Sankyo Co Ltd Sponsored ADR Level 1

2024-07-17 04:42:00 ET Summary As medical companies leverage the power of artificial intelligence, genomics, and other groundbreaking discoveries, the boundaries between technology and healthcare continue to blur, presenting potential opportunities for both patients and investors. ...

2024-07-02 11:20:47 ET Summary This article will outline nine steps I use to identify the most promising pharmaceutical companies and avoid investment pitfalls. In addition, each of the nine steps will provide examples of various factors and how they influence the assessment of th...

2024-06-27 07:56:32 ET More on Merck Merck & Co., Inc. (MRK) Goldman Sachs 45th Annual Global Healthcare Conference - (Transcript) Dividends And Innovation: Why Merck Is A Healthcare Stock Worth Buying Merck & Co., Inc. (MRK) Investor Event at ASCO 2024 (Tran...

2024-06-23 11:13:33 ET Summary Since the publication of my last article, Pfizer has continued to surprise me pleasantly. In early May, Pfizer published financial results for the first quarter of 2024, which were enthusiastically received by Wall Street. On June 14, 2024, the c...

2024-06-12 03:27:58 ET Summary Daiichi Sankyo is poised to play its part in revolutionizing cancer treatments with its portfolio of antibody-drug conjugates, that target $15 billion-plus annual revenue opportunities. Enhertu, the primary revenue driver today, has shown promising r...

2024-06-06 09:07:10 ET Summary AstraZeneca PLC showcased projects in two plenary lecture presentations at the Annual Meeting of the American Society of Clinical Oncology, or ASCO, including a trial that established osimertinib as the standard of care for EGFR-mutant NSCLC. Bristol...

Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig PR Newswire Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in ...

2024-05-28 12:29:50 ET More on AstraZeneca AstraZeneca: Plotting A Bold Path To $80 Billion Revenues, I'm Pausing For Breath AstraZeneca: A Triple Shot Of Income, Growth, And Value AstraZeneca: Strong In A Weak Market Nona Biosciences and AstraZeneca sign glo...

2024-05-18 14:52:07 ET More on GSK, Johnson & Johnson, etc. Shockwave Medical: A Look Into Q1 Financials And Value To Johnson & Johnson Investors Merck & Co., Inc. (MRK) BofA Securities 2024 Health Care Conference (Transcript) Johnson & Johnson (JNJ) ...

2024-04-26 12:15:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Strategy outperfor...